Literature DB >> 33348704

Current Trends in Cancer Immunotherapy.

Ivan Y Filin1, Valeriya V Solovyeva1, Kristina V Kitaeva1, Catrin S Rutland2, Albert A Rizvanov1,3.   

Abstract

The search for an effective drug to treat oncological diseases, which have become the main scourge of mankind, has generated a lot of methods for studying this affliction. It has also become a serious challenge for scientists and clinicians who have needed to invent new ways of overcoming the problems encountered during treatments, and have also made important discoveries pertaining to fundamental issues relating to the emergence and development of malignant neoplasms. Understanding the basics of the human immune system interactions with tumor cells has enabled new cancer immunotherapy strategies. The initial successes observed in immunotherapy led to new methods of treating cancer and attracted the attention of the scientific and clinical communities due to the prospects of these methods. Nevertheless, there are still many problems that prevent immunotherapy from calling itself an effective drug in the fight against malignant neoplasms. This review examines the current state of affairs for each immunotherapy method, the effectiveness of the strategies under study, as well as possible ways to overcome the problems that have arisen and increase their therapeutic potentials.

Entities:  

Keywords:  CAR T-cell therapy; cancer; cytokine therapy; immune checkpoint inhibitors; immunotherapy; oncolytic viruses; vaccines

Year:  2020        PMID: 33348704     DOI: 10.3390/biomedicines8120621

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  7 in total

1.  Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development.

Authors:  Tanapati Phakham; Chatikorn Boonkrai; Tossapon Wongtangprasert; Thittaya Audomsun; Chadaporn Attakitbancha; Pijitra Saelao; Phijitra Muanwien; Sarintip Sooksai; Nattiya Hirankarn; Trairak Pisitkun
Journal:  Sci Rep       Date:  2022-10-22       Impact factor: 4.996

Review 2.  Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.

Authors:  Joseph J Barchi
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561

3.  Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.

Authors:  Alexia Monastirioti; Chara Papadaki; Despoina Kalapanida; Konstantinos Rounis; Kleita Michaelidou; Maria A Papadaki; Dimitrios Mavroudis; Sofia Agelaki
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

Review 4.  Emerging Therapeutic Agents for Colorectal Cancer.

Authors:  Marianna Nalli; Michela Puxeddu; Giuseppe La Regina; Stefano Gianni; Romano Silvestri
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

Review 5.  Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice.

Authors:  Sabrina Orzetti; Federica Tommasi; Antonella Bertola; Giorgia Bortolin; Elisabetta Caccin; Sara Cecco; Emanuela Ferrarin; Elisa Giacomin; Paolo Baldo
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

Review 6.  Assessing the Future of Solid Tumor Immunotherapy.

Authors:  Prajna Guha; Kara R Heatherton; Kyle P O'Connell; Ian S Alexander; Steven C Katz
Journal:  Biomedicines       Date:  2022-03-11

7.  Identification and Validation of the Immune Regulator CXCR4 as a Novel Promising Target for Gastric Cancer.

Authors:  Shuai Xue; Ming Ma; Songhua Bei; Fan Li; Chenqu Wu; Huanqing Li; Yanling Hu; Xiaohong Zhang; YanQing Qian; Zhe Qin; Jun Jiang; Li Feng
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.